Novo Nordisk A/S - share repurchase programme

Bagsværd, Denmark, 22 July 2024– On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024. Under the programme...

Bagsvaerd, 22/07/2024 (informazione.news - comunicati stampa - salute e benessere)

– On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024.

Under the programme initiated 6 May 2024, Novo Nordisk will repurchase B shares for an amount up to DKK 2.2 billion in the period from 7 May 2024 to 5 August 2024.

Since the announcement 15 July 2024, the following transactions have been made:

The details for each transaction made under the share repurchase programme are published on novonordisk.com .

With the transactions stated above, Novo Nordisk owns a total of 11,984,827 B shares of DKK 0.10 as treasury shares, corresponding to 0.3% of the share capital. The total amount of A and B shares in the company is 4,465,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 20 billion during a 12-month period beginning 6 February 2024. As of 19 July 2024, Novo Nordisk has since 6 February 2024 repurchased a total of 10,619,037 B shares at an average share price of DKK 878.31 per B share equal to a transaction value of DKK 9,326,780,889.

Attachments